Tilray Brands Inc banner

Tilray Brands Inc
TSX:TLRY

Watchlist Manager
Tilray Brands Inc Logo
Tilray Brands Inc
TSX:TLRY
Watchlist
Price: 8.99 CAD -2.92% Market Closed
Market Cap: CA$1B

Tilray Brands Inc
Investor Relations

Tilray Brands Inc. emerged on the cannabis scene as a formidable player, carving its niche in a highly volatile yet promising industry. Founded amidst the wave of cannabis legalization sweeping across North America, Tilray quickly became one of the first companies to go public on a major U.S. stock exchange. The company has built its reputation through strategic mergers and acquisitions, most notably its merger with Aphria in 2021, which positioned it as a global leader with comprehensive scale and operational efficiencies. Headquartered in Canada, Tilray has extended its reach with production and distribution facilities not only in the Americas but also across Europe and Australia, capitalizing on the burgeoning medical cannabis market and expanding adult-use sectors. Its array of products spans from dried cannabis flowers and oils to edibles and beverages, catering to diverse consumer needs.

Tilray's core business model hinges on a vertically integrated approach, which enables it to oversee the entire supply chain – from cultivation and processing to distribution and sales. This model not only enhances product consistency and quality control but also improves margins by reducing dependency on third-party suppliers. The company primarily generates revenue through its extensive portfolio of brand offerings, including medical-grade products for healthcare providers and recreational products for consumers. Additionally, it has embraced strategic partnerships and diversified into the consumer health and wellness space, venturing into hemp-based foods and alcoholic beverages. By leveraging its global infrastructure and brand strength, Tilray continues to navigate the evolving regulatory landscapes, aiming to capture a significant share of the cannabis industry's projected growth.

Show more
Loading
TLRY
S&P TSX Composite Index (Canada)
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2026
Call Date
Apr 1, 2026
AI Summary
Q3 2026

Record quarter: Tilray reported third-quarter net revenue of $206.7 million, up 11% year over year, with gross profit of $55 million and adjusted EBITDA of $10.7 million, and it reaffirmed full-year adjusted EBITDA guidance of $62 million to $72 million.

International cannabis: The biggest growth engine was international cannabis, which reached $24.1 million in net sales, up 73% year over year, driven by higher volumes, stronger supply and continued expansion in markets like Germany.

Beer reset: Beverage revenue fell to $42.6 million, but management said Project 420 delivered $33 million of annualized cost savings and that the business is now at a trough margin level before the benefits of Carlsberg and BrewDog show up.

Strategic expansion: Tilray highlighted the BrewDog acquisition and Carlsberg partnership as major moves that expand its global beer platform and lift annualized revenue potential to about $1.2 billion.

Canada and Europe: Management said it is increasing cultivation capacity in Canada and improving yields in Europe to handle price pressure while improving supply consistency, especially in Germany.

Balance sheet: The company ended the quarter with $264.8 million in cash, restricted cash and marketable securities and a net cash position of $3.5 million, giving it flexibility to invest while staying disciplined.

Key Financials
Net revenue
$206.7 million
Gross profit
$55 million
Gross margin
27%
Adjusted EBITDA
$10.7 million
Cannabis net revenue
$64.8 million
International cannabis net sales
$24.1 million
Germany growth
43% year over year
Tilray Pharma revenue
$83 million
Canadian adult-use and medical cannabis revenue
almost $40 million
Beverage net revenue
$42.6 million
Beverage gross margin
32%
Wellness net revenue
$16.4 million
Wellness gross margin
33%
Distribution net revenue
$83 million
Distribution gross margin
12%
Net loss
$25.2 million
Net loss per share
$0.24
Adjusted net income
$2.4 million
Adjusted net income per share
$0.02
Adjusted cash operating income
$4.1 million
Cash flow used in operations
$21.9 million
Cash generated from operations excluding working capital
$3.4 million
Cash, restricted cash and marketable securities
$264.8 million
Net cash position
$3.5 million
Project 420 annualized savings
$33 million
Annualized cost savings during the quarter
over $6.2 million
Aluminum hedge
65% to 75%
International supply reallocation
approximately 6 metric tonnes
Pharmacy reach in Germany
16,000 pharmacies
BrewDog acquisition price
approximately EUR 40 million
BrewDog revenue taken on
between $225 million to $250 million
Beverage platform size
approximately $500 million
Annualized global revenue after BrewDog
approximately $1.2 billion
Other Earnings Calls

Management

Mr. Irwin David Simon
President, CEO & Chairman
No Bio Available
Mr. Carl A. Merton CA, CBV, CPA
CFO & Principal Accounting Officer
No Bio Available
Mr. Roger Savell
Chief Administrative Officer & CFO of International
No Bio Available
Mr. Mitchell S. Gendel J.D.
Global General Counsel & Corporate Secretary
No Bio Available
Ms. Denise Menikheim Faltischek
Chief Strategy Officer & Head of International
No Bio Available
Mr. Lloyd Brathwaite
Chief Information Officer
No Bio Available
Ms. Nyree Pinto
Chief Human Resources Officer
No Bio Available
Ms. Berrin Noorata
Chief Corporate Affairs Officer
No Bio Available
Mr. Blair MacNeil CMA, CPA
President of Tilray Canada
No Bio Available
Mr. Ty H. Gilmore
President of U.S. Beer
No Bio Available

Contacts

Address
NEW YORK
New York City
655 Madison Avenue, 19Th Floor
Contacts
+15193228800.0
www.tilray.com
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett